ZD4054 15 mg

DRUG2 trials

Sponsors

AstraZeneca

Conditions

Metastases, NeoplasmProstate CancerProstatic Neoplasms

Phase 2

A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 (Zibotentan) Given Orally Once Daily in Subjects With Metastatic Prostate Cancer

CompletedNCT00055471

AstraZenecaMetastases, Neoplasm, Prostatic Neoplasms

Start: 2003-06-30End: 2005-10-31Updated: 2012-10-31

ZD4054 (Zibotentan) in Pain-free or Mildly Symptomatic Patients With Prostate Cancer and Bone Metastases Who Have Rising Serum Prostate Specific Antigen (PSA)

CompletedNCT00090363

AstraZenecaProstate Cancer

Start: 2004-07-31End: 2011-08-31Updated: 2013-01-08

Related Papers

Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.

2008-11-29121 citations